Predictive Biosciences snaps up OncoDiagnostic Laboratory
This article was originally published in The Gray Sheet
Executive Summary
Acquisition of privately held, CLIA-certified anatomic pathology and molecular diagnostics lab OncoDiagnostic Laboratory for undisclosed terms on Jan. 7 by cancer test maker Predictive Biosciences will facilitate commercialization in 2010 of the latter firm's non-invasive molecular cancer diagnostic assays. The first assay will be a urine biomarker test for bladder cancer, Predictive Biosciences says. Cleveland-based OncoDiagnostic's "subspecialty expertise and national access to hundreds of urology practices [will] favorably position" Lexington, Mass.-based Predictive for launching its bladder cancer test "as well as future diagnostic products," including prostate and breast cancer assays, Predictive Biosciences explains